PHIO
Phio Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
PHIO Profile
Phio Pharmaceuticals Corp.
A clinical stage biotechnology company that develops therapeutics based on RNA interference
11 Apex Drive, Suite 300A PMB 2006, Marlborough, Massachusetts 01752
--
Phio Pharmaceuticals Corp. was incorporated in Delaware as a wholly-owned subsidiary of Galena on September 8, 2011 in preparation for the company's planned spin-off from Galena, which was completed on April 27, 2012. Since that date, the company has operated as an independent public company. Is a biotechnology company focused on the discovery, development and commercialization of innovative therapies based on the company's proprietary next-generation RNA interference (" RNAi ") platform. Therapeutic drugs using RNAi have great promise due to their ability to "silence" or down-regulate the expression of specific genes. Before September 8, 2011, the Company's business operated as an unincorporated division within Galena Biopharma, Inc. (" Galena "or the" Parent Company "), the former parent company of the Company.